Beneficial effects of pioglitazone against cardiovascular injury are enhanced by combination with aliskiren in a rat model of diabetic nephropathy

摘要: Objectives  Aliskiren is the first in a new class of orally active direct renin inhibitors, approved for treatment hypertension. However, efficacy aliskiren diabetic cardiovascular complications remains to be defined. This study aimed test hypothesis that may enhance beneficial effects pioglitazone against injury associated with nephropathy. Methods  Diabetic nephropathy was induced rats by unilateral nephrectomy followed streptozotocin injection. nephropathic were given vehicle, pioglitazone, aliskiren, or combined and four weeks compare their on injury, particularly myocardial fibrosis. Key findings  Pioglitazone significantly attenuated cardiac lipid peroxidation, oxidative fibrosis rats. up-regulation transforming growth factor-β1 matrix metalloproteinase-2 genes, along down-regulation tissue inhibitor gene tissue. The combination exerted greater effect than monotherapy either drug, all aforementioned parameters. Conclusions  Our findings suggested enhanced protective fibrosis, experimental nephropathy. Thus, potential therapeutic strategy